Investors Asset Management of Georgia Inc. GA ADV Has $402,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Investors Asset Management of Georgia Inc. GA ADV lessened its position in Bristol-Myers Squibb (NYSE:BMY) by 3.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,772 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Bristol-Myers Squibb were worth $402,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Trust Direct Indexing L.P. lifted its holdings in shares of Bristol-Myers Squibb by 52.1% during the first quarter. First Trust Direct Indexing L.P. now owns 22,320 shares of the biopharmaceutical company’s stock worth $1,210,000 after buying an additional 7,649 shares during the last quarter. Norden Group LLC boosted its holdings in Bristol-Myers Squibb by 30.2% in the 1st quarter. Norden Group LLC now owns 13,846 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 3,213 shares during the period. Janney Montgomery Scott LLC grew its position in Bristol-Myers Squibb by 10.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 939,078 shares of the biopharmaceutical company’s stock worth $50,926,000 after purchasing an additional 87,690 shares during the last quarter. Connecticut Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 7.2% during the 1st quarter. Connecticut Wealth Management LLC now owns 4,264 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 286 shares during the period. Finally, StoneX Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 4.2% in the first quarter. StoneX Group Inc. now owns 14,375 shares of the biopharmaceutical company’s stock valued at $780,000 after buying an additional 583 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. TD Cowen upped their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. UBS Group upped their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. BMO Capital Markets lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the stock a “market perform” rating in a research note on Friday. Jefferies Financial Group upped their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $53.08.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded down $1.45 during trading hours on Friday, reaching $54.32. 12,894,832 shares of the company were exchanged, compared to its average volume of 14,484,395. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The company has a market cap of $110.13 billion, a price-to-earnings ratio of -16.66, a P/E/G ratio of 14.62 and a beta of 0.46. The stock’s fifty day moving average is $51.26 and its two-hundred day moving average is $46.58. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $56.20.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $2.00 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.72 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.42%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is -73.62%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.